Geron Quits Stem Cell Research; Move Deemed Setback to the Field
In a surprise move, Geron today said it was terminating its stem cell business and what was the first-ever clinical trial of an hESC therapy, a potential product backed by a $25 million loan made by the California stem cell agency only six months ago.
Geron's move has "stark implications" for development of stem cell therapies in the United States, The …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.